編號
C3-002
徵稿主題
Clinical Trial / Chemotherapy / Targeted Therapy / Immunotherapy / Cell Therapy
題目
第一線 Osimertinib 於真實世界展現優於第二代 TKI 之存活率與經濟效益
作者群
陳柏瑝1,
李卓豪1,
陳佳宏1,
何景良2
服務單位
1 Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan
2 Division of Hematology and Oncology, Medical Department, Taipei Tzu Chi Hospital, Taipei, Taiwan
